# Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

> **NCT02152761** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 251 (actual)

## Conditions studied

- Muscle Wasting (Atrophy) After Hip Fracture Surgery

## Interventions

- **DRUG:** bimagrumab
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT02152761
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-16
- **Primary completion:** 2018-05-14
- **Final completion:** 2018-10-25
- **Target enrollment:** 251 (ACTUAL)
- **Last updated:** 2020-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02152761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02152761, "Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02152761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*